儿童高级别胶质瘤替莫唑胺治疗后的血液系统恶性肿瘤
该研究基于德语区儿科肿瘤血液学会HIT-HGG数据库的487例儿童高级别胶质瘤患者,随访超过1年。10年时继发性血液系统恶性肿瘤(SHM)发生率为7.7±3.2%。一线替莫唑胺治疗后194例中无SHM发生,但一线多药化疗后复发再使用替莫唑胺的131例中4例发生SHM(10年时20%,p=0.041);未使用替莫唑胺的多药化疗162例中2例发生SHM(10年时4.1%)。结论认为该队列数据未显示替莫唑胺治疗后SHM风险较既往化疗方案增加,但若在常规化疗后作为二线治疗使用,风险可能不成比例地增加。
要点
- 儿童高级别胶质瘤10年SHM发生率为7.7±3.2%。
- 一线替莫唑胺治疗后194例中无SHM发生。
- 一线多药化疗后复发再用替莫唑胺的131例中4例发生SHM(10年时20%,p=0.041)。
核心结论
- 该队列数据未显示替莫唑胺治疗后SHM风险较既往化疗方案增加,但若在常规化疗后作为二线治疗使用,风险可能不成比例地增加。
研究设计与样本
- 分析德语区儿科肿瘤血液学会HIT-HGG数据库中487例随访超过1年的儿童高级别胶质瘤患者。
主要发现
- 10年时SHM发生率为7.7±3.2%。
- 一线替莫唑胺治疗后194例中无SHM发生。
- 一线多药化疗后复发再使用替莫唑胺的131例中4例发生SHM(10年时20%,p=0.041)。
- 未使用替莫唑胺的多药化疗162例中2例发生SHM(10年时4.1%)。
- 性别、患者年龄及治疗期间急性血液学毒性未影响SHM发生率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Temozolomide (TMZ) is widely used in high-grade glioma (HGG). There is a major concern of treatment-induced secondary haematological malignancies (SHMs). Due to the poor overall survival of HGG patients, the true incidence is yet elusive. Thus, the aim of this study was to determine the risk of SHMs following TMZ in paediatric HGG. METHODS: We analysed 487 patients from the HIT-HGG database of the German-speaking Society of Pediatric Oncology and Hematology with follow up beyond 1 year. RESULTS: The incidence of SHM was 7.7 ± 3.2% at 10 years. No SHM occurred in 194 patients after first-line TMZ therapy, but four out of 131 patients treated with TMZ for relapse following first-line multiagent chemotherapy experienced SHM (20% at 10 years; p = 0.041). SHMs occurred in two out of 162 patients who underwent multiagent chemotherapy without TMZ (4.1% at 10 years). Gender, patient age and acute haematological toxicity during treatment did not affect the incidence of SHMs. CONCLUSION: Data of our cohort do not indicate an increased risk of SHM following TMZ treatment when compared to previous chemotherapy regimen. However, if TMZ is administered as a second-line treatment following conventional chemotherapy regimen, the risk might be disproportionately increasing.
引用
- Karremann M, Krämer N, Hoffmann M, et al. Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. Eur J Cancer. 2017. PMID: 28586748. doi:10.1016/j.ejca.2017.04.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。